

FACT SHEET

COMPANY PROFILE


Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX and SDax of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 4,224 employees (as of 30 September 2019) worldwide, the Group generated revenue of EUR 1,902.8m in fiscal year 2021/22 (as of 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.


SHARE CHART



SHAREHOLDER STRUCTURE



MANAGEMENT BOARD



SUPERVISORY BOARD

- > Dr. Karl Lamprecht
- > Falk Bindheim
- > Tania von der Goltz
- > Brigitte Koblizek
- > Jeffrey Marx
- > Dr. Christian Münster
- > René Denner
- > Isabel De Paoli
- > Peter Kameritsch
- > Heike Madan
- > Dr. Christian Müller
- > Torsten Reitze

STOCK FUNDAMENTALS

ISIN	DE0005313704
WKN	531370
Share type	Ordinary
Bloomberg Code	AFX@GR
Reuters Code	AFXG.DE
Ticker	AFX
Branch	Medical Technology
Index	MDAX, TecDAX
Segment	Prime Standard
Last Dividend	1.10 EUR (2021/22)
No. of shares	89,440,570
Market Cap	EUR 9.02 bn
52 week high	142.75 EUR
52 week low	72.60 EUR

FINANCIAL CALENDAR

Dec 12, 2023 Publication Annual Financial Report

FACT SHEET

HIGHLIGHTS ON A YEARLY BASIS¹

	2021/22		2020/21		2019/20		2018/19	
	€m	%	€m	%	€m	%	€m	%
Revenue	1.902,8	100	1.646,8	100	1.335,5	100	1.459,3	100
Research and development expenses	291,4	15,3	232,1	14,1	218,8	16,4	173,3	11,9
EBIT	396,9	20,9	373,6	22,7	177,6	13,3	264,7	18,1
Consolidated profit ¹	295,9	15,6	237,5	14,4	123,4	9,2	160,6	11,0
Earnings per share ² (in €)	3,29		2,64		1,37		1,79	
Dividend per share (in €)	1,10 ³		0,90 ³		0,50 ³		0,65	
Cash flows from operating activities	188,2		362,7		178,5		219,6	
Cash flows from investing activities	(148,9)		(71,2)		(71,9)		(145,8)	
Cash flows from financing activities	(38,2)		(289,9)		(123,0)		(58,6)	
Total assets	2.822,8	100	2.396,0	100	2.013,3	100	2.022,1	100
Property, plant and equipment	236,1	8,4	199,6	8,3	135,3	6,7	116,8	5,8
Equity	2.030,1	71,9	1.677,4	70,0	1.450,6	72,0	1.417,0	70,1
Net cash ⁴	885,6	30,3	939,9	39,2	707,2	35,1	677,8	33,5
Employees at end of reporting period (30 September)	4.224		3.531		3.290		3.232	

¹ Before non-controlling interests

² Profit/(loss) per share attributable to the shareholders of the parent company in the fiscal year

³ Amount proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG

⁴ Cash and cash equivalents plus treasury receivables from/payables to the treasury of Carl Zeiss AG

Carl Zeiss Meditec AG

Göschwitzer Str. 51-52
07745 Jena
Deutschland
www.zeiss.de/meditec-ag/ir
investors.meditec@zeiss.com

Contact Investor Relations

Sebastian Frericks
Director Investor Relations
Phone: +49 (0) 36 41 / 2 20 -1 16
Fax: +49 (0) 36 41 2 20 - 1 17
E-Mail: investors.meditec@zeiss.com
Sebastian Frericks
Director Investor Relations
Phone: +49 (0) 36 41 / 2 20 -1 16
Fax: +49 (0) 36 41 2 20 - 1 17
E-Mail: investors.meditec@zeiss.com